Stryker Corporation (NYSE:SYK) Receives Average Recommendation of “Moderate Buy” from Brokerages

Stryker Corporation (NYSE:SYK) has been assigned a consensus rating of “Moderate Buy” from the eighteen research firms that are presently covering the company, MarketBeat reports. Six equities research analysts have rated the stock with a hold recommendation and twelve have assigned a buy recommendation to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $431.8333.

Several research analysts have recently commented on the company. Evercore ISI decreased their price objective on Stryker from $410.00 to $405.00 and set an “outperform” rating on the stock in a report on Friday, October 31st. Truist Financial lifted their price target on Stryker from $392.00 to $400.00 and gave the stock a “hold” rating in a research note on Friday, November 14th. Royal Bank Of Canada reiterated an “outperform” rating and issued a $435.00 price objective on shares of Stryker in a research report on Friday, November 14th. Redburn Partners set a $420.00 target price on shares of Stryker in a report on Thursday, September 18th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $410.00 target price on shares of Stryker in a research note on Friday, November 14th.

Insider Transactions at Stryker

In other Stryker news, Director Ronda E. Stryker sold 276,173 shares of the stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $353.28, for a total value of $97,566,397.44. Following the completion of the sale, the director owned 2,702,108 shares in the company, valued at approximately $954,600,714.24. This trade represents a 9.27% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CAO William E. Berry, Jr. sold 1,953 shares of Stryker stock in a transaction that occurred on Friday, November 14th. The stock was sold at an average price of $365.49, for a total value of $713,801.97. Following the completion of the sale, the chief accounting officer owned 2,833 shares in the company, valued at approximately $1,035,433.17. This represents a 40.81% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 522,118 shares of company stock worth $185,381,932. Company insiders own 5.90% of the company’s stock.

Institutional Trading of Stryker

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Brighton Jones LLC increased its position in shares of Stryker by 15.4% during the fourth quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock valued at $1,643,000 after buying an additional 609 shares during the period. Vestmark Advisory Solutions Inc. boosted its position in Stryker by 136.6% during the 1st quarter. Vestmark Advisory Solutions Inc. now owns 4,304 shares of the medical technology company’s stock valued at $1,602,000 after acquiring an additional 2,485 shares in the last quarter. Kovitz Investment Group Partners LLC grew its holdings in shares of Stryker by 47.9% during the 1st quarter. Kovitz Investment Group Partners LLC now owns 11,948 shares of the medical technology company’s stock worth $4,448,000 after acquiring an additional 3,871 shares during the period. Horizon Investments LLC lifted its stake in shares of Stryker by 7.0% in the 1st quarter. Horizon Investments LLC now owns 8,294 shares of the medical technology company’s stock valued at $3,087,000 after purchasing an additional 542 shares during the period. Finally, EverSource Wealth Advisors LLC boosted its position in shares of Stryker by 19.5% during the first quarter. EverSource Wealth Advisors LLC now owns 1,756 shares of the medical technology company’s stock valued at $654,000 after purchasing an additional 287 shares in the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Trading Up 0.3%

SYK stock opened at $353.99 on Friday. Stryker has a one year low of $329.16 and a one year high of $406.19. The company has a market capitalization of $135.37 billion, a PE ratio of 46.52, a price-to-earnings-growth ratio of 2.51 and a beta of 0.89. The company’s 50 day moving average price is $366.81 and its two-hundred day moving average price is $378.46. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.13 and a current ratio of 1.85.

Stryker (NYSE:SYK) last released its earnings results on Thursday, October 30th. The medical technology company reported $3.19 EPS for the quarter, beating the consensus estimate of $3.13 by $0.06. The company had revenue of $6.06 billion for the quarter, compared to analyst estimates of $6.04 billion. Stryker had a net margin of 12.07% and a return on equity of 24.07%. The firm’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same quarter last year, the firm earned $2.87 EPS. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. As a group, analysts predict that Stryker will post 13.47 earnings per share for the current fiscal year.

Stryker Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 30th. Stockholders of record on Wednesday, December 31st will be paid a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 1.0%. This is a positive change from Stryker’s previous quarterly dividend of $0.84. The ex-dividend date of this dividend is Wednesday, December 31st. Stryker’s payout ratio is currently 44.15%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.